经18F标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描和多参数磁共振成像评估后对选定患者行无穿刺活检的前列腺根治术:一项单中心、前瞻性、单臂试验
本研究旨在验证无穿刺活检前列腺根治术的可行性和短期预后。47例PSA 4-30 ng/mL、PI-RADS≥4且PSMA评分≥2的cT2N0M0患者接受机器人辅助腹腔镜前列腺根治术,所有mpMRI和PSMA PET阳性患者均诊断为临床显著前列腺癌,mpMRI联合PSMA PET发现的指示肿瘤与病理符合率为95.7%,9例切缘阳性。结论认为严格经mpMRI联合18F-PSMA PET/CT评估后无活检前列腺根治术安全可行。
要点
- 47例cT2N0M0患者经mpMRI和18F-PSMA PET/CT评估后行无活检机器人辅助前列腺根治术。
- 所有mpMRI和PSMA PET阳性患者均诊断为临床显著前列腺癌。
- mpMRI联合PSMA PET发现的指示肿瘤与病理符合率为95.7%(45例),9例切缘阳性。
核心结论
- 对于严格经mpMRI联合18F-PSMA PET/CT评估的患者,无活检前列腺根治术安全可行。
研究设计与样本
- 单中心、前瞻性、单臂试验,纳入47例PSA 4-30 ng/mL、cT2N0M0、PI-RADS≥4且分子影像PSMA评分≥2的患者。
- 所有候选者接受机器人辅助腹腔镜前列腺根治术,未行穿刺活检。
主要发现
- 所有mpMRI和PSMA PET阳性的患者均诊断为临床显著前列腺癌。
- 病理证实80个癌灶,其中63个为临床显著前列腺癌。
- 51个病灶被mpMRI和PSMA PET同时发现。
- 23个病灶在两种影像上均不可见,所有病灶均≤ISUP 2级或≤15 mm。
- mpMRI联合PSMA PET发现的45个(95.7%)指示肿瘤与病理一致。
关键数值与推荐
- 纳入标准:PSA 4-30 ng/mL、cT2N0M0、PI-RADS≥4、分子影像PSMA评分≥2。
- 影像不可见病灶均≤ISUP 2级或≤15 mm。
- 指示肿瘤定位符合率为95.7%(45/47)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to verify the feasibility and short-term prognosis of prostatectomy without biopsy. MATERIALS AND METHODS: Patients with a rising PSA level ranging from 4 to 30 ng/mL were scheduled for multiparametric (mp) MRI and 18F-labeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET). Forty-seven patients (cT2N0M0) with Prostate Imaging Reporting and Data System ≥ 4 and molecular imaging PSMA score ≥ 2 were enrolled. All candidates underwent robot-assisted laparoscopic radical prostatectomy without biopsy. Prostate cancer detection rate, index tumors localization correspondence rate, positive surgical margin, complications, postoperative hospital stay, and PSA level in a 6-week postoperative follow-up visit were collected. RESULTS: All the patients with positive mpMRI and PSMA PET were diagnosed with clinically significant prostate cancer. A total of 80 lesions were verified as cancer by pathology, of which 63 cancer lesions were clinically significant prostate cancer. Fifty-one lesions were simultaneously found by mpMRI and PSMA PET. A total of 23 lesions were invisible on either image, and all lesions were ≤ International Society of Urological Pathology 2 or ≤ 15 mm. Forty-five (95.7%) index tumors found by mpMRI combined with PSMA PET were consistent with pathology. Nine patients reported positive surgical margin. CONCLUSIONS: Biopsy-free prostatectomy is safe and feasible for patients with evaluation strictly by mpMRI combined with 18F-PSMA PET/CT.
引用
- Niu S, Ding X, Liu B, et al. Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective, Single-Arm Trial. J Urol. 2024. PMID: 38885328. doi:10.1097/JU.0000000000004025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。